SecBot SecBot
SECBOTREPLAY Home › Report › XERS

XERS · Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and…

Xeris Biopharma Holdings, Inc. · 8-K filed Aug 6, 2026 at 07:12 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 6, 2026 at 07:12 ET

Xeris Biopharma reported Q2 2026 total revenue of $92.1M (+29% YoY) and net product revenue of $91.0M (+34% YoY), driven by Recorlev's 81% growth to $56.8M. The GAAP net loss of $31.1M was largely due to a $31M non-cash charge from convertible note exchange agreements, while Adjusted EBITDA improved to $19.3M. The company tightened full-year 2026 revenue guidance to $385-390M, reflecting confidence in continued commercial momentum, and eliminated all remaining 2028 Convertible Notes debt through cash and stock exchanges, strengthening the balance sheet.

  • Total revenue of $92.1M in Q2 2026, up 29% YoY from $71.5M
  • Net product revenue of $91.0M, up 34% YoY, driven by Recorlev (+81% to $56.8M)
  • GAAP net loss of $31.1M includes a ~$31M non-cash charge from convertible note exchange agreements
  • Adjusted EBITDA improved 54% to $19.3M from $12.5M in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access